Vertex Pharma (VRTX) Provides Updates on Multiple Kidney Programs

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. FIX
9. TSCO
10. BE

Go back to Vertex Pharma (VRTX) Provides Updates on Multiple Kidney Programs

Vertex Provides Updates on Multiple Kidney Programs at the American Society of Nephrology (ASN) Annual Kidney Week Congress

October 25, 2024 1:00 PM EDT

- New data on povetacicept 80 mg SC Q4 weeks in IgA nephropathy shows mean UPCR reduction from baseline of 66% observed at 48 weeks, associated with stable renal function (eGFR) and 63% achieving clinical remission --

- First proteinuria data on povetacicept in primary membranous nephropathy shows mean UPCR reduction from baseline of 62% at 24 weeks

- Global Phase 3 RAINIER trial of povetacicept in IgA nephropathy now underway

Enrollment and dosing ongoing in Phase 3 portion of the global Phase 2/3 pivotal... More